Report Description Table of Contents Introduction And Strategic Context The Global Molecular Imaging Market is slated for CAGR of 8.2%, rising from approximately $5.9 billion in 2024 to nearly $9.5 billion by 2030, accelerated by AI, radiotracers, diagnostics, PET, and theranostics as cited by Strategic Market Research. Molecular imaging is a specialized discipline that enables the visualization, characterization, and measurement of biological processes at the molecular and cellular levels in humans and other living systems. Unlike traditional imaging modalities that focus on anatomical changes, molecular imaging techniques such as PET (Positron Emission Tomography) , SPECT (Single Photon Emission Computed Tomography) , and hybrid systems like PET/CT and PET/MRI allow early disease detection, patient-specific treatment planning, and the monitoring of treatment efficacy. Strategic Importance of Molecular Imaging (2024–2030) The global molecular imaging market holds strategic significance due to its deep integration with precision medicine, oncology diagnostics, neurological disease mapping, and cardiovascular disease assessment. As healthcare continues to evolve toward individualized treatments and early diagnosis, the demand for non-invasive and highly accurate imaging techniques has surged. Molecular imaging also plays a pivotal role in drug discovery and translational research, making it indispensable for pharmaceutical innovation pipelines. In 2024, the market is witnessing exponential growth due to four primary macro drivers: Rising Global Cancer Burden : Molecular imaging is a frontline tool in oncology, aiding in the diagnosis, staging, and monitoring of various cancers. Technological Advancements : Integration of AI in image analysis, improvements in radiotracers, and hybrid imaging systems are transforming diagnostic precision. Government Funding and Institutional Research : National institutes and collaborative global networks are investing heavily in nuclear medicine research and radiopharmaceutical production. Aging Population and Chronic Disease Prevalence : With the rise in Alzheimer’s, Parkinson’s, and cardiovascular conditions, molecular imaging facilitates early and more accurate diagnoses. Stakeholder Landscape Key stakeholders in the molecular imaging ecosystem include: key Original Equipment Manufacturers (OEMs) producing PET, SPECT, and hybrid scanners Radiopharmaceutical developers synthesizing novel tracers and isotopes Healthcare providers including hospitals, diagnostic centers, and oncology clinics Academic and research institutes driving innovation through clinical studies Regulatory agencies such as FDA, EMA, and IAEA guiding safety and approval pathways Investors and VC firms funding AI-imaging startups and biotech collaborations “The real power of molecular imaging lies in its ability to detect disease before symptoms manifest, paving the way for true preventive medicine,” says a nuclear medicine researcher at a leading cancer institute. Comprehensive Market Snapshot The Global Molecular Imaging Market is slated for CAGR of 8.2%, rising from approximately $5.9 billion in 2024 to nearly $9.5 billion by 2030. The USA Molecular Imaging Market will register a healthy 7.4% CAGR, expanding from $1.65 billion in 2024 to ~$2.53 billion by 2030. The Europe Molecular Imaging Market will grow at 6.8% CAGR, expanding from $1.71 billion in 2024 to ~$2.54 billion by 2030. The APAC Molecular Imaging Market will grow at 9.2% CAGR, expanding from $1.24 billion in 2024 to ~$2.10 billion by 2030. Market Segmentation Insights By Modality Positron Emission Tomography (PET) accounted for approximately 42% of the total market share in 2024, driven by its high sensitivity, quantitative capabilities, and indispensable role in oncology diagnosis, staging, and therapy response monitoring. Single Photon Emission Computed Tomography (SPECT) represented nearly 27% of market revenue, supported by its broad installed base, cost-effectiveness, and continued use in cardiology and bone imaging. Hybrid Imaging Systems held about 23% share and are projected to grow at the fastest CAGR over 2024–2030, led by increasing adoption of PET/CT and PET/MRI for combined anatomical–molecular assessment in neurology, pediatrics, and precision oncology. Others accounted for approximately 8% of the market, reflecting niche use of emerging and adjunct molecular imaging techniques in research-oriented settings. By Application Oncology remained the leading application area, accounting for approximately 55% of total market demand in 2024, underpinned by routine use in tumor detection, metastasis evaluation, and longitudinal treatment monitoring. Cardiology represented around 15% of the market, supported by molecular perfusion imaging and viability assessment in ischemic heart disease. Neurology captured nearly 14% share, reflecting growing use of molecular imaging in Alzheimer’s disease, Parkinson’s disease, epilepsy, and other CNS disorders. Inflammation & Infectious Diseases accounted for approximately 8%, driven by targeted tracer development for infection localization and inflammatory pathway mapping. Drug Discovery contributed about 8% of market revenue and is expected to grow at a strong pace, supported by increasing use of molecular imaging in target validation, pharmacodynamics, and translational research. By End User Hospitals & Clinics accounted for approximately 48% of total market revenue in 2024, driven by integrated imaging infrastructure, reimbursement coverage, and high diagnostic procedure volumes. Diagnostic Imaging Centers represented nearly 22% of the market, reflecting the shift of routine PET and SPECT scans toward outpatient settings. Academic & Research Institutes held about 16% share, supported by government-funded research programs, neuroscience imaging, and tracer development initiatives. Pharmaceutical & Biotechnology Companies accounted for approximately 14% and are projected to witness the fastest growth, driven by expanding molecular imaging use in drug discovery, clinical trials, and biomarker-driven development programs. Regional Insights Europe accounted for the largest market share at 29% in 2024, supported by strong nuclear medicine infrastructure, early technology adoption, and public healthcare reimbursement for PET-based diagnostics. Asia–Pacific is expected to expand at the fastest CAGR during 2024–2030, driven by rapid healthcare infrastructure expansion, rising cancer prevalence, and increasing investments in advanced diagnostic imaging. Strategic Questions Guiding the Evolution of the Global Molecular Imaging Market What imaging modalities, tracer classes, and clinical applications are explicitly included within the Global Molecular Imaging Market, and which adjacent diagnostic, anatomical imaging, or research-only tools are out of scope? How does the Molecular Imaging Market differ structurally from adjacent diagnostic imaging markets such as conventional radiology, ultrasound, and purely anatomical CT/MRI imaging? What is the current and forecasted size of the Global Molecular Imaging Market, and how is value distributed across PET, SPECT, hybrid imaging systems, and emerging platforms? How is revenue allocated between standalone imaging systems, hybrid imaging platforms, radiopharmaceuticals, and associated software, and how is this mix expected to evolve over the forecast period? Which application areas (e.g., oncology, cardiology, neurology, inflammation & infectious diseases, and drug discovery) account for the largest and fastest-growing revenue pools? Which segments generate disproportionate profit and margin expansion relative to scan volume, particularly across high-value tracers and advanced hybrid systems? How does demand differ between routine clinical diagnostics, advanced precision imaging, and research-driven molecular imaging use cases? How are first-line diagnostic imaging, confirmatory imaging, and advanced molecular imaging procedures evolving within clinical care pathways? What role do scan frequency, follow-up imaging, and longitudinal monitoring play in driving recurring revenue across key molecular imaging segments? How are disease prevalence, diagnosis rates, and access to advanced imaging infrastructure shaping demand across regions and clinical settings? What clinical, regulatory, or radiotracer supply-chain constraints limit adoption in specific modalities or geographic markets? How do reimbursement policies, pricing pressure, and payer scrutiny influence utilization rates and revenue realization for molecular imaging procedures? How robust is the current and mid-term pipeline of novel radiotracers and imaging agents, and which targets or mechanisms are likely to open new clinical indications? To what extent will new tracers expand the addressable patient population versus intensify competition within established imaging applications? How are advances in detector technology, image reconstruction software, and AI-enabled analytics improving diagnostic accuracy, workflow efficiency, and clinical value? How will system replacement cycles, technology obsolescence, and platform upgrades reshape competitive dynamics among imaging equipment vendors? What role will generic or follow-on radiopharmaceuticals play in pricing dynamics, access expansion, and margin compression? How are leading companies aligning their imaging system portfolios, tracer development strategies, and service models to defend or grow market share? Which geographic regions are expected to outperform global growth in the Molecular Imaging Market, and which clinical applications or technologies are driving this outperformance? How should imaging manufacturers, radiopharmaceutical developers, healthcare providers, and investors prioritize modalities, applications, and regions to maximize long-term value creation? Segment-Level Insights and Market Structure The Molecular Imaging Market is structured around distinct imaging modalities and end-user settings that reflect differences in clinical purpose, technological complexity, capital intensity, and integration within healthcare and research ecosystems. Each segment contributes uniquely to overall market value, competitive positioning, and long-term growth potential, shaped by diagnostic complexity, disease focus, and the evolving role of precision medicine. Modality Insights Positron Emission Tomography (PET) PET represents the most value-dense segment within the molecular imaging market, anchored by its high sensitivity and quantitative capability to visualize biological processes at the molecular level. Clinically, PET is deeply embedded in oncology workflows for staging, therapy selection, and treatment response assessment. From a market perspective, PET systems and associated radiotracers generate recurring revenue streams through scan volume, tracer consumption, and service contracts. While PET adoption is already mature in developed markets, incremental growth is being driven by new tracer development and expanding indications beyond oncology. Single Photon Emission Computed Tomography (SPECT) SPECT remains a widely utilized modality, particularly in cardiology, bone imaging, and functional studies. Its continued relevance is supported by a large installed base, lower system costs relative to PET, and established clinical protocols. Commercially, SPECT contributes steady volume-driven revenue rather than high-margin growth, with utilization closely tied to routine diagnostic demand. Over time, its role is expected to remain stable, with incremental upgrades and hybrid configurations sustaining its presence in clinical practice. Hybrid Imaging Systems Hybrid imaging systems, including PET/CT and PET/MRI, represent the most innovation-driven modality segment. These platforms integrate anatomical and molecular data, enabling higher diagnostic confidence and broader clinical utility. Market growth in this segment is supported by demand for precision diagnostics in neurology, pediatrics, and complex oncology cases where multi-parametric imaging is required. Hybrid systems are capital-intensive but strategically important, as they drive higher system replacement value, software upgrades, and long-term service revenues. Other Molecular Imaging Modalities Other modalities occupy a niche position within the market, primarily serving research-oriented or highly specialized clinical applications. Their adoption is often limited to academic centers or innovation hubs exploring novel imaging techniques or experimental tracers. While these modalities contribute modestly to overall revenue, they play a critical role in early-stage technology validation and long-term innovation pipelines. Application-Level Insights Oncology Oncology is the dominant application area for molecular imaging, reflecting its central role in tumor detection, disease staging, and therapy monitoring. Molecular imaging supports clinical decision-making across the cancer care continuum, making it indispensable in modern oncology pathways. From a market standpoint, oncology imaging drives both equipment utilization and radiotracer demand, positioning it as the primary revenue anchor of the market. Cardiology Cardiology represents a stable and well-established application segment, particularly for perfusion imaging and functional assessment. Utilization is closely tied to ischemic heart disease management and risk stratification. While growth is more moderate compared to oncology, cardiology imaging contributes consistent procedure volumes and supports sustained demand for SPECT and PET-based solutions. Neurology Neurology is emerging as a high-growth application segment, supported by increasing focus on neurodegenerative diseases and central nervous system biomarkers. Molecular imaging is gaining importance in differentiating disease subtypes and supporting clinical research in Alzheimer’s and Parkinson’s disease. This segment is increasingly associated with advanced imaging platforms and research-driven adoption. Inflammation, Infection, and Drug Discovery Imaging applications in inflammation, infectious diseases, and drug discovery represent smaller but strategically important segments. These use cases are closely tied to tracer innovation, translational research, and pharmaceutical development. Growth in these areas reflects the expanding role of molecular imaging beyond diagnostics into therapy development and precision research. End-User Insights Hospitals and Clinics Hospitals and clinics form the backbone of molecular imaging utilization, supported by integrated diagnostic infrastructure, reimbursement mechanisms, and high patient throughput. These settings account for the majority of routine clinical imaging procedures and anchor demand for both standalone and hybrid imaging systems. Their purchasing decisions are influenced by clinical breadth, system reliability, and long-term operating economics. Diagnostic Imaging Centers Diagnostic imaging centers play a growing role, particularly in outpatient imaging and routine follow-up scans. Their market relevance is driven by operational efficiency, patient convenience, and the decentralization of imaging services. While capital investment is more selective, these centers contribute meaningfully to scan volume and service-based revenue. Academic and Research Institutes Academic and research institutions represent a critical innovation-driven segment. Their adoption of molecular imaging is tied to clinical research, neuroscience studies, and tracer development programs. Although their share of total revenue is smaller, they influence technology validation, early adoption of novel platforms, and long-term market evolution. Pharmaceutical and Biotechnology Companies Pharmaceutical and biotechnology companies are an emerging end-user segment, leveraging molecular imaging for drug discovery, target validation, and clinical trial optimization. Their engagement is expanding as imaging becomes integral to precision medicine and biomarker-driven development strategies. This segment is expected to contribute disproportionately to future growth due to its research intensity and willingness to adopt advanced imaging solutions. Segment Evolution Perspective While established modalities and hospital-based use cases continue to anchor current market demand, growth is increasingly shaped by hybrid imaging platforms, neurology applications, and research-driven end users. The market is gradually shifting from volume-led diagnostics toward value-driven precision imaging, with innovation in tracers, software, and system integration influencing how value is distributed across segments over the forecast period. Key Commercial Platforms and High-Value Tracers in the Molecular Imaging Market Product / Platform (Representative Brand) Company Development Status Target / Mechanism of Action (Device Modality) Discovery MI / Omni Legend (PET/CT platform family) GE HealthCare Marketed (commercial) Digital PET/CT (SiPM-based detectors); high-sensitivity, high-throughput PET with quantitative oncology and neurology workflows Biograph Vision (PET/CT platform) Siemens Healthineers Marketed (commercial) Digital PET/CT (SiPM); ultra-high sensitivity and temporal resolution for oncology and advanced quantitative imaging Vereos PET/CT Philips Marketed (commercial) Digital PET/CT (SiPM); improved time-of-flight and quantification (PET photon-counting claims apply to CT, not PET) uMI PET/CT platform family (uMI series) United Imaging Marketed (commercial) Digital PET/CT (SiPM); scalable, high-sensitivity systems supporting oncology and multi-tracer clinical adoption SIGNA PET/MR GE HealthCare Marketed (commercial) Hybrid PET/MRI; simultaneous acquisition combining PET molecular data with high soft-tissue MRI (neuro, peds, complex oncology) Biograph mMR (PET/MR) Siemens Healthineers Marketed (commercial) Hybrid PET/MRI; simultaneous PET/MR for multi-parametric neuro and research imaging Discovery NM/CT (SPECT/CT platform family) GE HealthCare Marketed (commercial) Hybrid SPECT/CT; CT-based attenuation correction and anatomical localization for cardiology, bone, and oncology SPECT Symbia Intevo (SPECT/CT) Siemens Healthineers Marketed (commercial) Hybrid SPECT/CT; workflow-optimized nuclear medicine platform for routine and advanced SPECT studies BrightView XCT / SpectrumCT (SPECT/CT) Philips Marketed (commercial) Hybrid SPECT/CT; general nuclear imaging with CT-based localization and correction D-SPECT (cardiac-focused CZT SPECT) Spectrum Dynamics Medical Marketed (commercial) CZT detector SPECT; dedicated cardiac imaging with high count sensitivity and reduced acquisition times Cardiolite (99mTc-sestamibi) Lantheus Approved / Marketed Myocardial perfusion SPECT; mitochondrial uptake proportional to perfusion for ischemia assessment Myoview (99mTc-tetrofosmin) GE HealthCare Approved / Marketed Myocardial perfusion SPECT; stress/rest perfusion imaging tracer DaTscan (¹²³I-ioflupane) GE HealthCare Approved / Marketed Dopamine transporter SPECT; evaluates striatal DAT binding in parkinsonian syndromes Illuccix (68Ga-gozetotide kit) Telix Pharmaceuticals Approved / Marketed PSMA PET; PSMA targeting for prostate cancer staging and recurrence localization Pylarify (¹8F-DCFPyL) Lantheus Approved / Marketed PSMA PET; F-18–based prostate cancer imaging enabling broad distribution Posluma (¹8F-flotufolastat) Blue Earth Diagnostics Approved / Marketed PSMA PET; prostate cancer lesion detection and disease mapping Netspot (68Ga-DOTATATE) Advanced Accelerator Applications Approved / Marketed Somatostatin receptor PET (SSTR2); neuroendocrine tumor localization Axumin (¹8F-fluciclovine) Blue Earth Diagnostics Approved / Marketed Amino-acid PET; amino-acid transport imaging for prostate cancer recurrence Cerianna (¹8F-fluoroestradiol) GE HealthCare Approved / Marketed Estrogen receptor PET; maps ER expression in metastatic breast cancer Amyvid (¹8F-florbetapir) Eli Lilly / Avid Radiopharmaceuticals Approved / Marketed Amyloid PET; beta-amyloid plaque detection for Alzheimer’s diagnostic evaluation Vizamyl (¹8F-flutemetamol) GE HealthCare Approved / Marketed Amyloid PET; beta-amyloid plaque imaging in cognitive disorder assessment Neuraceq (¹8F-florbetaben) Life Molecular Imaging Approved / Marketed Amyloid PET; beta-amyloid plaque visualization for dementia workups Tauvid (¹8F-flortaucipir) Eli Lilly / Avid Radiopharmaceuticals Approved / Marketed Tau PET; imaging of aggregated tau pathology in Alzheimer’s disease Flurpiridaz F-18 Lantheus Late-stage clinical / region-dependent Mitochondrial complex I PET tracer; high-resolution myocardial perfusion imaging with PET workflow advantages Key Recent Developments GE HealthCare FDA approval of Flyrcado PET myocardial perfusion tracer (USA) GE HealthCare secured FDA approval for Flyrcado (flurpiridaz F 18) for PET evaluation of myocardial ischemia/infarction—an important step in shifting cardiac perfusion imaging toward PET-based workflows where throughput, quantitation, and image quality can be value-defining. CE Mark for Omni 128cm total-body PET/CT (Europe) GE HealthCare announced CE Mark for its Omni 128cm total-body PET/CT, signaling renewed investment in ultra-wide axial FOV systems that can enable faster scans, lower dose protocols, and dynamic multi-organ imaging—a platform shift with direct implications for oncology and theranostics workflows. Siemens Healthineers New Biograph Trinion PET/CT debuted at SNMMI (Global) Siemens Healthineers introduced Biograph Trinion, positioning it as a next-generation PET/CT with emphasis on time-of-flight performance, operational efficiency, and lower lifetime operating costs—a clear “performance + sustainability” product thesis for replacement and new-install demand. New Biograph One PET/MR introduced at RSNA (Global) Siemens launched Biograph One (PET/MR), reinforcing that PET/MR remains a strategic growth lane where simultaneous anatomy/function/metabolism can differentiate use cases in theranostics, neurology, and complex oncology—especially at advanced academic and referral centers. Telix Illuccix label expansion enabling PSMA-therapy patient selection (Australia) Telix reported an Australian TGA label expansion for Illuccix, aligning PSMA-PET imaging more tightly with downstream PSMA-targeted radioligand therapy selection—a direct “diagnostic-to-therapy pathway” catalyst that can lift PSMA imaging utilization where treatment capacity is expanding. Illuccix approved in Germany with broad prostate-cancer imaging label (Germany/EU) Telix announced Illuccix approval in Germany, strengthening its European footprint in a market that has historically been influential in PSMA-PET clinical practice—supporting broader access to gallium-based PSMA imaging workflows. Phase 3 registration-enabling “BiPASS” study initiated (Australia → expansion to U.S.) Telix disclosed first patient dosing in BiPASS, a Phase 3 registration-enabling study combining MRI with PSMA-PET aimed at improving diagnostic pathways and expanding indications for its PSMA PET agents—signaling continued push to widen clinical utility beyond “standard staging/restaging.” Lantheus Acquisition of Life Molecular Imaging to scale amyloid PET footprint (USA/Global) Lantheus announced plans to acquire Life Molecular Imaging, a move that consolidates capabilities around Alzheimer’s-focused PET imaging (and related pipeline) and reflects accelerating strategic value of neuro PET tracers + distribution scale. Lantheus + GE HealthCare Japan licensing deal for PYLARIFY (Japan) Lantheus and GE HealthCare announced an exclusive licensing agreement for PYLARIFY in Japan, including transfer of dossiers/manufacturing know-how—highlighting how market expansion increasingly depends on local radiopharmaceutical manufacturing networks and regulatory execution. Curium Acquisition of Nucleis to expand PET manufacturing capacity and distribution (Europe) Curium acquired Nucleis to expand PET manufacturing capacity and strengthen distribution across Western Europe, explicitly tying the deal to improved availability and CDMO support for new PET tracers—an operational development that matters because reliability of supply directly governs scan volumes. Life Molecular Imaging + PharmaLogic Neuraceq supply expansion for regional access (USA) Life Molecular Imaging and PharmaLogic expanded Neuraceq availability through additional manufacturing/distribution nodes (e.g., Cincinnati), reflecting a broader industry pattern: tracer access is becoming a competitive advantage, not just scanner performance. Blue Earth Diagnostics + Siemens POSLUMA clinical data shared to support AI algorithm development (USA/Global) Blue Earth Diagnostics signed a data-sharing agreement with Siemens Healthineers to use anonymized POSLUMA clinical data/images for AI-based algorithm development—showing how radiopharmaceutical companies are increasingly partnering upstream with imaging OEMs to improve interpretation confidence and workflow standardization. Blue Earth Diagnostics CMS payment reform push for diagnostic radiopharmaceutical access (USA) Blue Earth Diagnostics highlighted CMS OPPS-related payment changes aimed at improving reimbursement for certain diagnostic radiopharmaceuticals—an important commercial lever because reimbursement policy can rapidly alter site adoption, scan volumes, and tracer pull-through. Market Segmentation And Forecast Scope The molecular imaging market is structured across four key segmentation pillars: By Modality , By Application , By End User , and By Region . Each dimension captures a distinct facet of how molecular imaging solutions are developed, deployed, and consumed in healthcare and research settings. Below is a detailed breakdown of the segmentation logic and forecast scope. By Modality Molecular imaging modalities differ in sensitivity, resolution, and the type of physiological processes they can detect. The major categories include: Positron Emission Tomography (PET) Single Photon Emission Computed Tomography (SPECT) Hybrid Imaging Systems (PET/CT, PET/MRI, SPECT/CT) Others (including emerging optical and magnetic particle imaging) PET dominates the modality segment, accounting for approximately 42% of the market share in 2024, driven by its superior sensitivity and its critical role in oncology. However, hybrid imaging systems represent the fastest-growing category, particularly PET/MRI , which combines high spatial resolution with molecular data, essential for neurological and pediatric imaging. By Application Applications define the clinical or research use cases where molecular imaging delivers the most impact. The primary applications include: Oncology Cardiology Neurology Inflammation & Infectious Diseases Drug Discovery & Development Oncology is the single largest application area, projected to retain over 55% market share in 2024. This dominance stems from molecular imaging's critical role in tumor detection, staging, and monitoring therapeutic response. On the other hand, neurology and drug discovery are emerging as high-growth segments, especially with rising interest in Alzheimer's and Parkinson’s biomarkers. By End User End users reflect the institutional buyers and operational environments for molecular imaging systems: Hospitals & Clinics Diagnostic Imaging Centers Academic & Research Institutes Pharmaceutical & Biotechnology Companies Hospitals & Clinics currently lead the segment due to integrated infrastructure, reimbursement access, and procedural volume. Meanwhile, academic institutes and pharma/biotech firms are gaining momentum, thanks to research-oriented imaging trials and increasing tracer development pipelines. By Region Geographically, the molecular imaging market is segmented into: North America Europe Asia Pacific LAMEA (Latin America, Middle East, and Africa) North America holds the largest regional share owing to advanced healthcare systems, strong reimbursement frameworks, and the presence of leading OEMs and radiopharmaceutical developers. However, Asia Pacific is forecast to grow at the fastest pace through 2030 due to improving diagnostic infrastructure, rising healthcare spending, and increased adoption of precision medicine in countries like China, Japan, and South Korea. “The regional shift in research capital and manufacturing of isotopes toward Asia could rebalance the innovation footprint in molecular imaging over the next five years,” notes an industry analyst specializing in radiopharmaceuticals. Market Trends And Innovation Landscape The molecular imaging market is undergoing a transformation shaped by rapid technological convergence, radiopharmaceutical innovation, and AI-driven analytics. From hybrid imaging platforms to AI-based reconstruction algorithms and next-generation tracers, the innovation landscape is deepening the diagnostic precision and expanding the clinical scope of molecular imaging. Technological Convergence and Hybrid Modalities One of the most significant trends is the surge in hybrid imaging platforms . Modalities like PET/CT and PET/MRI are now considered gold standard in oncology and neurology respectively. These systems merge functional and anatomical data, improving lesion detection and anatomical localization, particularly in complex tumor environments or brain imaging. Hybrid systems are being miniaturized and optimized for bedside use in intensive care units (ICUs) and intraoperative guidance during surgeries—expanding molecular imaging into procedural medicine. “PET/MRI is revolutionizing neuro-oncology by enabling structural, functional, and metabolic mapping within a single scan window,” commented a senior radiologist from a university hospital in Europe. AI-Powered Imaging and Workflow Automation Artificial intelligence is increasingly being deployed in: Image reconstruction : Enhancing image clarity at lower doses Lesion detection and classification Quantitative analytics and reporting Radiomics and predictive modeling AI-driven tools reduce diagnostic subjectivity and turnaround time while enabling longitudinal analysis of disease progression. This is especially critical in cancer treatment where subtle changes in tumor metabolism can guide therapeutic adjustments. Furthermore, cloud-based PACS (Picture Archiving and Communication Systems) integrated with AI models allow remote consultation, enabling decentralized imaging workflows. Radiopharmaceutical Innovation and New Tracers The development of novel radiotracers is expanding the utility of molecular imaging beyond fluorodeoxyglucose (FDG). Emerging areas include: Neuroimaging tracers : For amyloid plaques, tau proteins, and dopamine receptors Immuno-PET agents : Targeting immune checkpoint proteins and tumor microenvironments Theranostic isotopes : Dual-purpose agents used for both diagnostics and targeted therapy (e.g., Lutetium-177) “The approval of novel PSMA-targeted PET agents for prostate cancer is a game-changer in urological oncology,” according to a molecular oncology researcher from the U.S. National Institutes of Health. Cross-Industry Collaborations and Start-Up Growth There is growing synergy between imaging OEMs , radiopharmaceutical firms , AI startups , and academic research centers . Notable trends include: Co-development of new PET tracers for specific cancers and neurological conditions Partnerships between imaging hardware makers and cloud-AI analytics platforms Investment in microfluidics and isotope manufacturing for point-of-care tracer production These collaborative efforts are accelerating product development and regulatory approvals, shortening time to clinical use. Competitive Intelligence And Benchmarking The molecular imaging market features a dynamic and specialized competitive landscape, where companies differentiate themselves through technological prowess, radiopharmaceutical pipelines, geographic footprint, and strategic collaborations. The space is dominated by a mix of global imaging OEMs , nuclear medicine specialists , and radiotracer developers . Here are seven key players reshaping the molecular imaging domain: 1. Siemens Healthineers A global powerhouse in hybrid imaging systems, Siemens Healthineers leads in the development of PET/CT and PET/MRI solutions. The company is known for its Biograph Vision platform and has integrated AI-driven workflow automation into its imaging systems. Siemens also focuses on quantitative imaging biomarkers , and its strong European and U.S. base gives it robust market leverage. 2. GE HealthCare GE HealthCare is a formidable player with a broad portfolio in SPECT , PET , and hybrid imaging platforms. Through its Discovery IQ and Omni Legend product lines, the company is emphasizing faster image acquisition and lower radiation doses. GE also offers radiopharmaceutical manufacturing systems and is heavily invested in AI-assisted analytics and enterprise imaging software. 3. Canon Medical Systems A rising force in PET/MRI and digital PET , Canon Medical is innovating on compact system designs tailored for neurology and pediatric imaging. The firm is also exploring photon-counting detectors for better spatial resolution. Canon’s strong presence in Asia and its increasing partnerships with research institutions have helped it gain traction in molecular imaging research ecosystems. 4. Bracco Imaging An industry leader in radiopharmaceuticals, Bracco Imaging focuses on tracer development and contrast agents, especially for PET and SPECT applications. Its Blue Earth Diagnostics division has been pivotal in the launch of PSMA-targeted agents for prostate cancer. Bracco’s end-to-end value chain includes manufacturing, regulatory, and distribution, giving it a vertically integrated advantage. 5. Cardinal Health Through its nuclear pharmacy network , Cardinal Health is a major distributor of radiopharmaceuticals across North America. While not an equipment manufacturer, its logistics and production capabilities are critical to delivering just-in-time isotopes for PET/SPECT scans. Cardinal’s reliability and scale make it a preferred partner for hospitals and imaging centers. 6. Curium Pharma Headquartered in Europe, Curium Pharma is a leading player in the SPECT radiopharmaceutical space. The company is rapidly expanding into theranostic tracers , focusing on isotopes like Lutetium-177. Curium is known for its agile production facilities and strong regulatory credentials, making it a key supplier in both established and emerging markets. 7. SOFIE Biosciences An innovation-focused company, SOFIE Biosciences develops PET tracers , especially for neurology and immunology applications. The firm is advancing theranostic platforms and is involved in translational research partnerships with academic centers. SOFIE’s nimbleness and deep R&D orientation give it a strong foothold in niche, high-value molecular imaging niches. “The competitive race is shifting from machine specifications to software intelligence and tracer innovation—whoever controls the algorithm and the isotope wins,” notes a senior industry strategist at a diagnostic consortium. Regional Landscape And Adoption Outlook The adoption of molecular imaging technologies varies significantly across regions due to differences in healthcare infrastructure, regulatory frameworks, reimbursement models, and academic research intensity. While North America continues to dominate in overall revenue, Asia Pacific is emerging as a high-growth frontier, and Europe is characterized by strong radiopharmaceutical innovation and public healthcare access. North America North America —particularly the United States —accounts for the largest share of the molecular imaging market in 2024. This dominance stems from: Advanced hospital and diagnostic infrastructure Strong reimbursement policies for PET and SPECT procedures Active clinical trial ecosystems, particularly in oncology and neurology Strategic presence of key players like GE HealthCare , Cardinal Health , and Bracco Imaging The U.S. Food and Drug Administration (FDA) has also accelerated the approval of novel tracers such as PSMA-targeted agents and amyloid PET ligands , boosting clinical adoption. Moreover, federal funding through programs like the Cancer Moonshot Initiative has spurred investment in nuclear medicine innovation. Europe Europe exhibits a well-established molecular imaging network, particularly in countries such as Germany , France , and Switzerland . The region benefits from: Government-backed research initiatives in radiopharmaceuticals Large-scale PET/CT installation in university hospitals Collaboration among academic centers and tracer manufacturers like Curium Pharma However, adoption speed varies significantly across Eastern Europe due to disparities in imaging infrastructure and funding. Countries such as the Netherlands and Belgium lead in AI-imaging pilot projects and theranostic research. “In Europe, regulatory harmonization via EMA is helping streamline tracer approvals across borders, which enhances adoption across smaller markets,” noted a regulatory consultant at a biotech firm. Asia Pacific The Asia Pacific region is the fastest-growing market for molecular imaging, driven by increasing awareness, a surge in chronic diseases, and expanding healthcare investment. Key growth drivers include: Rising cancer burden in China , India , and South Korea Government funding for radiopharmaceutical production facilities Accelerated installation of PET/CT and SPECT/CT in tertiary care centers China has launched regional isotope production hubs and is supporting domestic OEMs to boost self-reliance in hybrid imaging systems. Japan , with its aging population, is expanding PET/M RI systems for neurodegenerative disease diagnosis, while South Korea is leading in AI-based diagnostic imaging platforms. Academic collaborations and growing access to advanced radiology education are further enhancing the talent pool and innovation pipeline in this region. “Asia Pacific’s rise in molecular imaging is not just about volume, but sophistication—South Korea and Japan are pushing the envelope in AI fusion and precision neurology,” shared a healthcare futurist at a global imaging symposium. LAMEA (Latin America, Middle East, and Africa) While the LAMEA region holds a smaller share of the global molecular imaging market, it presents significant white space and untapped opportunities , particularly in oncology-focused diagnostics. The main trends include: Brazil and Mexico making strides in PET/CT adoption for cancer centers United Arab Emirates and Saudi Arabia investing in nuclear medicine hubs as part of healthcare diversification South Africa developing partnerships with academic institutions to expand tracer production However, barriers such as high equipment costs , limited isotope access , and regulatory delays hinder wider adoption. Capacity building and public-private partnerships remain crucial for regional expansion. Comparative Outlook Region 2024 Market Share Growth Outlook (2024–2030) Key Drivers North America Highest Stable Growth Reimbursement, R&D, OEM presence Europe Moderate Moderate Growth Radiopharma R&D, public healthcare Asia Pacific High Fastest Growth Cancer incidence, healthcare spend LAMEA Low Emerging Infrastructure gaps, tracer shortage End-User Dynamics And Use Case The molecular imaging market serves a diverse group of end users, each with distinct operational models, clinical goals, and capital capabilities. Understanding how these end users integrate molecular imaging technologies offers critical insight into purchasing behavior, system preferences, and unmet needs across clinical and research environments. Hospitals and Clinics Hospitals and clinics represent the largest and most stable end-user segment for molecular imaging systems. These institutions perform high volumes of PET and SPECT procedures, especially for oncology, cardiology, and neurology . Large urban hospitals typically maintain in-house radiopharmacy units or rely on third-party nuclear pharmacies for daily isotope supply. Preferred modalities: PET/CT, SPECT/CT Key considerations: Reimbursement eligibility, image throughput, maintenance support Growing trend: Integration of AI-powered diagnostic platforms for multi-specialty departments “We rely on molecular imaging every day in our tumor board decisions—PET/CT findings often determine whether a patient goes to surgery or chemo,” shared the Chief of Oncology at a U.S. tertiary hospital. Diagnostic Imaging Centers These centers are often specialized, outpatient facilities that focus on high-efficiency, volume-driven imaging services. Their operational model emphasizes: Cost-effectiveness and rapid report turnaround Scalable systems with minimal downtime Partnerships with radiopharmacies for isotope delivery As value-based care models expand, diagnostic centers are investing in low-dose imaging systems and automated scheduling/reporting tools to boost throughput while reducing radiation exposure. Academic and Research Institutions Research institutions play a pivotal role in tracer development , clinical trials , and novel protocol validation . They often deploy cutting-edge systems like PET/MRI and are early adopters of AI and theranostic technologies. Their use cases include: Studying neurodegenerative disease progression Testing novel immune-targeted PET ligands Developing AI models using radiomics datasets Academic users are less price-sensitive but highly demanding in terms of customization , data export capabilities , and regulatory transparency for investigational imaging agents. Pharmaceutical and Biotechnology Companies Pharma and biotech firms use molecular imaging tools extensively in: Preclinical drug screening Patient stratification for clinical trials Therapeutic response monitoring PET/SPECT imaging supports biomarker-based trial design , particularly in immunotherapy and targeted therapy domains. Companies often form imaging core labs or partner with contract research organizations (CROs) for regulatory-grade imaging in global trials. Realistic Use Case: Precision Imaging in South Korea A tertiary hospital in Seoul, South Korea, deployed a PET/MRI platform integrated with AI-assisted segmentation tools to monitor glioblastoma progression in brain tumor patients. By combining structural, metabolic, and molecular data, clinicians were able to adjust treatment protocols based on early metabolic shifts—leading to a 16% improvement in patient-specific survival planning. This use case exemplifies how AI-enhanced molecular imaging empowers clinicians with actionable insights earlier in the treatment cycle, a critical factor for aggressive diseases like brain cancer. Recent Developments + Opportunities & Restraints Recent Developments (Last 2 Years) FDA Approval of Radiohybrid PSMA PET Agent : In 2023, the FDA approved a novel radiohybrid PSMA PET imaging agent for prostate cancer, enhancing specificity and reducing false positives. GE HealthCare Unveils Omni Legend PET/CT System : GE launched the Omni Legend platform offering ultra-fast scanning and deep-learning-based noise reduction. Siemens Healthineers Launches Biograph Vision Quadra in Asia : This total-body PET/CT system improves scan times and opens new avenues for pharmacokinetic modeling. Curium and Singapore’s A*STAR Launch Radiopharmaceutical R&D Center : A 2024 partnership aims to fast-track theranostic agents for oncology across Southeast Asia. Canon Medical Systems Introduces Photon Counting PET Detectors : First clinical trials began in late 2023 focusing on improved resolution in low-dose pediatric scans. Opportunities Theranostic Integration : The convergence of diagnostic imaging with targeted radiotherapy opens new revenue streams and patient personalization pathways. AI and Radiomics Growth : Rising demand for predictive imaging biomarkers creates an opportunity for AI-enabled molecular imaging analytics platforms. Isotope Manufacturing in Emerging Markets : Governments and private firms in Asia and Latin America are investing in local isotope production, reducing reliance on imports. Restraints High Capital and Operational Costs : Advanced PET/MRI and hybrid systems involve significant upfront and maintenance expenses, limiting adoption in smaller healthcare settings. Tracer Shelf-Life and Supply Chain Challenges : Radiotracers have short half-lives, and disruptions in production or delivery can delay patient scans, especially in underserved regions. 7.1. Report Coverage Table Report Attribute Details Forecast Period 2024 – 2030 Market Size Value in 2024 USD 5.9 Billion Revenue Forecast in 2030 USD 9.5 Billion Overall Growth Rate CAGR of 8.2% (2024 – 2030) Base Year for Estimation 2024 Historical Data 2019 – 2023 Unit USD Million, CAGR (2024 – 2030) Segmentation By Modality, By Application, By End User, By Geography By Modality PET, SPECT, Hybrid Imaging Systems, Others By Application Oncology, Cardiology, Neurology, Inflammation & Infectious Diseases, Drug Discovery By End User Hospitals & Clinics, Diagnostic Imaging Centers, Academic & Research Institutes, Pharmaceutical & Biotechnology Companies By Region North America, Europe, Asia-Pacific, LAMEA Country Scope U.S., UK, Germany, China, India, Japan, Brazil, etc. Market Drivers - Rising cancer and neurodegenerative disease burden - Technological innovation in imaging and radiotracers - AI integration and precision diagnostics Customization Option Available upon request Frequently Asked Question About This Report Q1: How big is the molecular imaging market? A1: The global molecular imaging market was valued at USD 5.9 billion in 2024. Q2: What is the CAGR for the molecular imaging market during the forecast period? A2: The market is expected to grow at a CAGR of 8.2% from 2024 to 2030. Q3: Who are the major players in the molecular imaging market? A3: Leading players include Siemens Healthineers, GE HealthCare, and Bracco Imaging. Q4: Which region dominates the molecular imaging market? A4: North America leads due to strong infrastructure, reimbursement models, and radiotracer accessibility. Q5: What factors are driving the molecular imaging market? A5: Growth is fueled by rising disease burden, AI-enhanced diagnostics, and radiopharmaceutical innovation. Executive Summary Market Overview Market Attractiveness by Modality, Application, End User, and Region Strategic Insights from Key Executives (CXO Perspective) Historical Market Size and Future Projections (2022–2030) Summary of Market Segmentation by Modality, Application, End User, and Region Market Share Analysis Leading Players by Revenue and Market Share Market Share Analysis by Modality, Application, and End User Investment Opportunities in the Molecular Imaging Market Key Developments and Innovations Mergers, Acquisitions, and Strategic Partnerships High-Growth Segments for Investment Market Introduction Definition and Scope of the Study Market Structure and Key Findings Overview of Top Investment Pockets Research Methodology Research Process Overview Primary and Secondary Research Approaches Market Size Estimation and Forecasting Techniques Market Dynamics Key Market Drivers Challenges and Restraints Impacting Growth Emerging Opportunities for Stakeholders Impact of Behavioral and Regulatory Factors Government Policy Support and Global Innovation Networks Global Molecular Imaging Market Analysis Historical Market Size and Volume (2022–2023) Market Size and Volume Forecasts (2024–2030) Market Analysis by Modality: PET SPECT Hybrid Imaging Systems Others Market Analysis by Application: Oncology Cardiology Neurology Inflammation & Infectious Diseases Drug Discovery & Development Market Analysis by End User: Hospitals & Clinics Diagnostic Imaging Centers Academic & Research Institutes Pharmaceutical & Biotechnology Companies Market Analysis by Region: North America Europe Asia-Pacific LAMEA Regional Market Analysis North America Molecular Imaging Market U.S., Canada, Mexico Market Size and Volume Forecasts (2024–2030) Regional Trends, Policy Landscape, and Adoption Rates Europe Molecular Imaging Market Germany, United Kingdom, France, Italy, Spain, Rest of Europe Institutional Collaborations and Radiopharma Pipelines Asia-Pacific Molecular Imaging Market China, India, Japan, South Korea, Rest of Asia-Pacific Investments in Nuclear Medicine and Hybrid Modalities Latin America, Middle East & Africa (LAMEA) Brazil, Argentina, GCC Countries, South Africa, Rest of LAMEA Barriers, White Space Mapping, and Strategic Expansion Potential Key Players and Competitive Analysis Siemens Healthineers GE HealthCare Canon Medical Systems Bracco Imaging Cardinal Health Curium Pharma SOFIE Biosciences Benchmarking of Strategic Initiatives and Innovation Portfolios Appendix Abbreviations and Terminologies Used in the Report References and Sources List of Tables Market Size by Modality, Application, End User, and Region (2024–2030) Regional Market Breakdown by Country and Segment (2024–2030) List of Figures Market Dynamics: Drivers, Restraints, Opportunities Regional Market Snapshot for Key Geographies Competitive Landscape and Market Share Growth Strategies Adopted by Key Players Market Share by Segment (2024 vs. 2030)